Tucked away inside Obamacare are 18 pages that could create a new $20 billion-per-year market.
Keep Reading →
June 4 - News
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has built a unique, winning drug business by acquiring underperforming niche product franchises and incorporating them into its efficient...
Keep Reading →
May 28 - News
Currently, a majority of pharma companies are facing the issue of generic competition.
Keep Reading →
May 28 - News
Drug companies have been revenue generating machines for long.
Keep Reading →
May 22 - News
The real-money Inflation-Protected Income Growth portfolio saw yet another gain last week, this time picking up around $711 -- or better than 2.3% of the $30,000 it started with...
Keep Reading →
May 20 - News
Whether or not you've been keeping tabs, the American Society of Clinical Oncology's annual meeting is less than two weeks away.
Keep Reading →
May 20 - News
News that Montreal-based Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was in talks to merge with Parsippany, New Jersey-based Actavis Inc (NYSE:ACT) emerged barely a week after...
Keep Reading →
May 15 - News
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated.
Keep Reading →
May 15 - News
The first official recognition of Mother's Day occurred nearly a century ago, when on May 9, 1914, President Woodrow Wilson proclaimed the second Sunday in May would thereafter...
Keep Reading →
May 9 - News
Antares Pharma Inc (NASDAQ:ATRS) announced its first-quarter results Wednesday morning but failed to impress the market. Shares were down around 3% in midday trading.
Keep Reading →
May 8 - News
Actavis Inc (NYSE:ACT), the largest generic drug company in the US, just got even bigger.
Keep Reading →
May 1 - News
When it comes to biotechs, Amgen, Inc. (NASDAQ:AMGN) qualifies for the senior citizen discount.
Keep Reading →
April 24 - News
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), a pharmaceuticals company that makes money off of branded drugs as well as generics, is an interesting example of a company...
Keep Reading →
April 23 - News
On Tuesday, Amgen, Inc. (NASDAQ:AMGN) will release its latest quarterly results.
Keep Reading →
April 21 - News
Johnson & Johnson (NYSE:JNJ) has been considered a dividend growth star for a number of years now.
Keep Reading →
April 18 - News
Abbott Laboratories (NYSE:ABT) has begun its new future swimmingly.
Keep Reading →
April 5 - News
Last November, I examined five experimental drugs that appeared as if they had all of the tools necessary to become life-changing blockbusters from a financial and quality of ...
Keep Reading →
March 28 - News
In this series, we'll highlight four companies in an industry, and compare their "cash king margins" over time, trying to determine which has the greatest likelihood of putting...
Keep Reading →
March 27 - News
Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap.
Keep Reading →
March 26 - News
Will good news from Europe echo on this side of the Atlantic within the next few days? Biogen Idec Inc. (NASDAQ:BIIB) is certainly hoping so.
Keep Reading →
March 25 - News
In early December 2012, the Inflation-Protected Income Growth portfolio was launched.
Keep Reading →
March 25 - News
The Biopharmaceutical industry has been one of the most profitable industries last year.
Keep Reading →
March 20 - News
There were cheers for joy when Abbott Laboratories (NYSE:ABT) announced that it would split itself into two entities -- separating the device and diagnostics businesses from ...
Keep Reading →
March 19 - News
U.S. generics firm Actavis Inc (NYSE:ACT), previously Watson Pharmaceuticals, reported a strong jump in its revenues in the fourth quarter and total earnings for 2012.
Keep Reading →
March 17 - News
With interest rates still sitting near record lows, investors looking for current income have been forced to move from fixed income positions and into stocks to find yield.
Keep Reading →
March 14 - News
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) is hurting today after dialing back guidance for the year. Apparently the increased production by Sagent Pharmaceuticals Inc.
Keep Reading →
March 13 - News
Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap.
Keep Reading →
March 11 - News
Earnings season is winding down, with most companies already having reported their quarterly results.
Keep Reading →
March 11 - News
It took more than five years, but the Dow Jones Industrial Average 2 Minute (Dow Jones Indices: .DJI) has officially surpassed its previous record.
Keep Reading →
March 8 - News
Ultimately, that was the loss of those optimists. As value investors, we are not afraid of bad news as long as we get compensated by low valuations.
Keep Reading →
March 7 - News
Motley Fool health care analyst Max Macaluso and Fool contributor Brian Orelli sat down to discuss Amarin Corporation plc (ADR) (NASDAQ:AMRN) , a biotech that recently launched...
Keep Reading →
March 6 - News
Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap.
Keep Reading →
March 5 - News
Every investor can appreciate a stock that consistently beats the Street without getting ahead of its fundamentals and risking a meltdown.
Keep Reading →
February 26 - News
Elan Corporation, plc (ADR) (NYSE:ELN) was nice enough to give us a little more detail on what it plans to do with the $3.25 million that the biotech stands to get from Biogen...
Keep Reading →
February 25 - News
Between the patent cliff, taxes, and Europe's meltdown, there's enough information and legislation swirling about to keep concerned shareholders up for days.
Keep Reading →
February 21 - News
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company NewLink Genetics Corp...
Keep Reading →
February 20 - News
Last week, the Inflation-Protected Income Growth portfolio received its first dividend payment, $9.87 worth of dividends on 47 shares of Texas Instruments Incorporated (NASDAQ...
Keep Reading →
February 20 - News
Biogen Idec Inc.(NASDAQ:BIIB) has just moved to reinforce its dominance in the multiple sclerosis treatment market by striking a deal to buy the 50% rights to Tysabri that it...
Keep Reading →
February 19 - News
Earnings season is now starting to wind down, with most companies already having reported their quarterly results.
Keep Reading →
February 19 - News
The biotechnology industry is one of the most attractive industries for investors primarily due to its high returns.
Keep Reading →
February 14 - News
Back in 2011, generic drug giant Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) dominated the MS field, riding the coattails of its Copaxone medication to success.
Keep Reading →
February 14 - News
Here at The Motley Fool, we believe the best way to invest and maximize returns is by buying strong companies and owning them for a long time.
Keep Reading →
February 11 - News
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, specialty pharmaceutical company Depomed...
Keep Reading →
February 11 - News
One thing's for sure: You'll never discover truly great investments unless you actively look for them.
Keep Reading →
February 11 - News
Its narcolepsy drug Provigil saw generic competition from Par Pharmaceutical Companies, Inc. (NYSE:PRX) and Mylan Inc.
Keep Reading →
February 9 - News
One thing's for sure: You'll never discover truly great investments unless you actively look for them.
Keep Reading →
February 8 - News
The patent cliff has positively impacted the valuations of small biopharmaceutical companies due to their acquisition potential.
Keep Reading →
February 8 - News
Biogen Idec Inc. (NASDAQ:BIIB) is buying the full rights to multiple sclerosis drug Tysabri from Elan Corporation, plc (ADR) (NYSE:ELN) for $3.25 billion.
Keep Reading →
February 6 - News
On one hand, you have multibillion-dollar enterprises like AbbVie Inc (NYSE:ABBV) that boast a deep bench of drugs, massive profit margins, and mountains of cash on the balance...
Keep Reading →
February 6 - News
Earnings season is in full swing, with huge numbers of companies having already given their latest numbers to investors.
Keep Reading →
February 6 - News